|1.||Desaphy, Jean-François: 5 articles (02/2015 - 01/2004)|
|2.||Hanna, Michael G: 4 articles (12/2015 - 01/2011)|
|3.||Kuwabara, Satoshi: 4 articles (09/2015 - 04/2003)|
|4.||Kuraishi, Yasushi: 4 articles (11/2008 - 05/2002)|
|5.||Matthews, Emma: 3 articles (12/2015 - 01/2011)|
|6.||Lentini, Giovanni: 3 articles (10/2015 - 02/2012)|
|7.||Egashira, Nobuaki: 3 articles (09/2015 - 01/2010)|
|8.||Misawa, Sonoko: 3 articles (09/2015 - 02/2005)|
|9.||Kawashiri, Takehiro: 3 articles (09/2015 - 01/2010)|
|10.||Statland, Jeffrey M: 3 articles (01/2015 - 10/2012)|
05/01/1990 - "Multiple studies have shown that as monotherapy mexiletine is effective in preventing the induction of ventricular tachycardia in approximately 20% of patients. "
02/01/1988 - "Electrically-inducible ventricular tachycardia was suppressed by mexiletine alone in 23% of patients tested, and a combined antiarrhythmic drug regimen was effective in 29% of the trials performed. "
10/01/1977 - "Mexiletine, a new antiarrhythmic drug, was finally effective in controlling recurrent attacks of ventricular tachycardia."
07/01/1985 - "In conclusion, mexiletine is effective and safe in many patients with intractable ventricular tachycardia. "
02/01/1988 - "The efficacy of mexiletine used alone, and in combination with a class Ia antiarrhythmic drug, was assessed in 159 previously drug-refractory patients with ventricular tachycardia (VT) during serial electrophysiologic studies and during long-term (5-year) clinical follow-up. "
10/01/1997 - "A significant reduction in sleep disturbances and pain during nighttime was observed in the group of patients taking the highest dosages (675 mg/day) of mexiletine compared with the other groups. "
04/01/1992 - "Mexiletine was found to produce a statistically significant reduction in reported pain when compared to baseline or placebo. "
04/01/2009 - "Continued relief from pain, even after mexiletine was discontinued in this patient, might suggest that early treatment may slow the progression of the disease."
12/01/1990 - "Our findings suggest that mexiletine may be a safe and effective agent in the management of thalamic pain and possibly other paroxysmal pain syndromes of central origin."
06/01/1994 - "Subsequently, mexiletine was administered orally in a dose of 300 mg a day and the dose was increased up to 450 mg a day, by which a severity of pain was halved and anxiety was relieved one month later. "
|3.||Neuralgia (Stump Neuralgia)
09/05/1997 - "In addition, we tested the effect of mexiletine, a drug useful in the management of clinical neuropathic pain in this model. "
09/01/2000 - "However, recent reports question the efficacy of oral mexiletine in neuropathic pain. "
04/01/1992 - "The availability of the oral antiarrhythmic medication, mexiletine, has made it possible to study the effects of an orally administered medication on chronic neuropathic pain. "
11/01/2011 - "Although it is primarily used in treating ventricular arrhythmias, recent indications for use of mexiletine include chronic and neuropathic pains. "
07/01/2009 - "These findings rationalize the clinical use of mexiletine for treatment of neuropathic pain."
|4.||Cardiac Arrhythmias (Arrythmia)
07/27/1979 - "Orally administered mexiletine was found to be very effective in treatment of drug-resistant ventricular arrhythmias, with total abolition of arrhythmia in six and satisfactory control in two additional patients. "
02/01/1984 - "In serum from 38 patients receiving mexiletine for cardiac arrhythmia, concentrations measured by this method correlated with therapeutic efficacy."
01/01/1980 - "Mexiletine is effective in abolishing experimentally induced cardiac arrhythmias and belongs to the Vaughan-Williams Class I group of antiarrhythmic agents. "
02/01/1988 - "We conclude that the added efficacy and possible improved arrhythmia-free survival associated with combining mexiletine with a class Ia agent should be further investigated."
01/01/1985 - "[Efficacy of mexiletine in the long-term treatment of exertion arrhythmia]."
|5.||Ventricular Premature Complexes (Premature Ventricular Contraction)
01/01/1989 - "Mexiletine treatment resulted in a highly significant reduction in the mean number of premature ventricular beats from 163 to 28 and 30/24 h, respectively (p less than 0.01). "
05/01/1984 - "Our results show that: Propafenon is better tolerated; Propafenon has caused a statistically significant reduction of the total number of ventricular ectopic beats/24 hours; the efficacy of Propafenon has been greater than that of Mexiletine (66% and 25% respectively); with both drugs, in 2 cases, there was an increase of the total number of ventricular ectopic beats/24 hours; Propafenon has induced clear-cut electrocardiogram changes (statistically significant lengthening of P-Q and Q-T intervals)."
06/19/1978 - "Treatment for 1 week with mexiletine 600 mg daily resulted in a statistically significant reduction in ventricular ectopic beats, particularly during and after exercise; there were virtually no side-effects. "
04/01/1986 - "Mexiletine is as effective as traditional antiarrhythmics in the treatment of premature ventricular contractions. "
07/02/1993 - "(+/-)-Mexiletine is a class Ib antiarrhythmic drug useful in the treatment of premature ventricular contractions. "
|2.||Sodium Channels (Sodium Channel)
|2.||Drug Therapy (Chemotherapy)
|5.||Electric Countershock (Cardioversion)